BIT Capital GmbH Reduces Holdings in BridgeBio Pharma, Inc. $BBIO

BIT Capital GmbH cut its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 94.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,056 shares of the company’s stock after selling 16,504 shares during the quarter. BIT Capital GmbH’s holdings in BridgeBio Pharma were worth $55,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. L & S Advisors Inc acquired a new position in shares of BridgeBio Pharma in the 3rd quarter valued at $877,000. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of BridgeBio Pharma by 152.1% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 148,917 shares of the company’s stock worth $7,735,000 after buying an additional 89,856 shares during the last quarter. Vanguard Group Inc. increased its position in BridgeBio Pharma by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock valued at $874,257,000 after acquiring an additional 347,074 shares during the period. Assetmark Inc. increased its position in BridgeBio Pharma by 57.2% in the 3rd quarter. Assetmark Inc. now owns 4,418 shares of the company’s stock valued at $229,000 after acquiring an additional 1,608 shares during the period. Finally, Cibc World Market Inc. purchased a new stake in BridgeBio Pharma during the 3rd quarter valued at approximately $1,024,000. 99.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BBIO. Morgan Stanley initiated coverage on BridgeBio Pharma in a research note on Tuesday, January 6th. They set an “overweight” rating and a $96.00 price target for the company. Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the company an “outperform” rating in a report on Thursday, February 12th. Leerink Partners boosted their price target on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Evercore reissued an “outperform” rating on shares of BridgeBio Pharma in a report on Monday, October 27th. Finally, Barclays started coverage on BridgeBio Pharma in a report on Wednesday, January 28th. They issued an “overweight” rating on the stock. Twenty-two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $82.05.

Insider Buying and Selling

In related news, CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $71.94, for a total value of $2,877,600.00. Following the completion of the transaction, the chief executive officer owned 695,686 shares of the company’s stock, valued at approximately $50,047,650.84. The trade was a 5.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas Trimarchi sold 13,600 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. This trade represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 176,121 shares of company stock worth $13,009,631 in the last ninety days. 18.20% of the stock is currently owned by insiders.

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock opened at $70.72 on Friday. BridgeBio Pharma, Inc. has a fifty-two week low of $28.33 and a fifty-two week high of $84.94. The firm has a market capitalization of $13.63 billion, a price-to-earnings ratio of -16.92 and a beta of 1.13. The stock’s fifty day moving average is $75.66 and its two-hundred day moving average is $63.84.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL‑3 achondroplasia results improve the program’s regulatory and commercial outlook — a clear fundamental catalyst supporting upside for BBIO. Read More.
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and bumped its price target to $100 while keeping a Buy rating — analyst upgrades can lift sentiment and buying interest. Read More.
• Neutral Sentiment: Upcoming Q4/2025 earnings and Feb. 24 conference call create a scheduled event risk: results and program/cash‑burn details could drive short‑term volatility either way. Read More.
• Neutral Sentiment: Company granted inducement RSUs to new hires (76,701 shares) — modest ongoing dilution to monitor but not a large immediate overhang. Read More.
• Neutral Sentiment: Small institutional buying: Oppenheimer reported a new 7,845‑share stake per 13F filing — signals some investor interest but immaterial scale. Read More.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO sold 13,600 shares (~$1.02M), alongside other officer sales — concentrated disposals are pressuring near‑term sentiment. Read More.
• Negative Sentiment: Smaller CAO sale (510 shares) and a pattern of executive liquidity events — repeated sales by insiders can keep downward pressure until management rebuilds conviction via buying or other signals. Read More.
• Neutral Sentiment: Reported short‑interest data is inconsistent (entries show zero shares / NaN) and does not currently indicate a material short‑squeeze dynamic — treat the short‑interest note as noise until clearer reporting emerges.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.